Trial
NCT01662895
High-Dose Deferoxamine in Intracerebral Hemorrhage
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
Medical University of South Carolina; National Institute of Neurological Disorders and Stroke (NINDS); Massachusetts General Hospital; Tufts Medical Center; University of Massachusetts, Worcester; University of Pennsylvania; Johns Hopkins University; University of Maryland; University of Virginia; Duke University; University of North Carolina; University of Florida; The Cleveland Clinic; Henry Ford Hospital; Ohio State University; St. Joseph's Hospital and Medical Center, Phoenix; University of California, San Francisco; Oregon Health and Science University; Yale New Haven Hospital; University of Iowa; Hartford Hospital; The University of Texas Health Science Center, Houston; Rhode Island Hospital; Stanford University; University of Washington; University of Calgary; Hopital de l'Enfant-Jesus; University of Alberta; Dalhousie University
Condition
Intracerebral Hemorrhage
Intervention
Deferoxamine
Why stopped
By DSMB on October 18, 2013 due to increased incidence of ARDS. See modified protocol \[NCT02175225
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-06-12